- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 30.09. | Roche, Zealand Pharma see phase 2 amylin weight loss peak at mid-dose, start pivotal program | ||
| 30.09. | Lilly sets up next-gen obesity battle with full phase 3 retatrutide data | ||
| 29.09. | Enanta sheds staffers as key antiviral, immunology readouts loom | ||
| 29.09. | uniQure stock crashes as Huntington's gene therapy data weaken | ||
| 29.09. | Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui | ||
| 29.09. | AstraZeneca scales Summit's PD-1xVEGF strategy with $2B investment to fuel ADC combos | ||
| 28.09. | Roche drops muscle-sparing obesity antibody after flunked interim analysis | ||
| 28.09. | Mirum posts phase 3 hepatitis win for 'commercially differentiated' challenger to Gilead, Vir | ||
| 28.09. | Scynexis bags $214M BARDA contract for antifungal development | ||
| 28.09. | Kodiak's stock doubles as resurrected eye disease drug matches Eylea in phase 3 | ||
| 28.09. | Merck pens $2.1B deal with China's SciBrunch to chase KRAS G12D | ||
| 28.09. | Tolerance continues thymus-focused deals with $560M pact for Tanabe's clinical-stage IL-33 drug | ||
| 28.09. | Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal | ||
| 25.09. | Indivior ends PAM drug collab with Addex ahead of Supernus merger | ||
| 25.09. | Novo inks $1.3B Nanexa deal to unlock long-acting obesity injectables | ||
| 25.09. | Roche's Genentech inks $1.5B bispecific pact with fast-rising Earendil | ||
| 25.09. | ADARx scores upsized $446M IPO, while fellow RNA biotech City Therapeutics maps out Nasdaq plans | ||
| 24.09. | Trump's FDA pick Heidi Overton calls vaccines, mifepristone safe and effective in confirmation hearing | ||
| 24.09. | China's Henlius carves out $440M T-cell engager deal with Amberstone | ||
| 24.09. | Acadia misses mark in Alzheimer's but concludes phase 3 'absolutely worth' pursuing | ||
| 24.09. | Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs | ||
| 24.09. | Merck sees pivotal victory for $3B eye disease prospect | ||
| 24.09. | Lilly puts up $100M, plus billions on the backend, to form 5-target deal with InnoCare | ||
| 23.09. | Enveda reaps $311M series E to feed ambition to become a 'household name' | ||
| 23.09. | Trump's Department of War bets $47M on Flagship biotechs to develop countermeasures |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.